Pediatric-type Therapy With Pre-transplant Blinatumomab for HR Patients - Phase II Study
Status:
Recruiting
Trial end date:
2025-05-01
Target enrollment:
Participant gender:
Summary
Despite recent therapeutic advancements, the outcome of young adults with
Philadelphia-negative (Ph-neg) acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma
(LBL) remains unsatisfactory, especially in those patients with high-risk disease features.
In young adults pediatric-based chemotherapy approaches improve outcome. Furthermore, there
is evidence that pre-transplant antibody-based therapy may render patients with positive
minimal residual disease (MRD+) to an MRD-negative status (MRD-) and that this may be
associated with improved post-transplant outcome.
This is prospective study to evaluate the potential benefit of a modified pediatric-based
approach in young adults with Ph-neg ALL. Safety and efficacy of pre-transplant
antibody-based consolidation in high-risk patients with Ph-neg ALL will be performed.